PA
TAK icon

Pinnacle Associates’s Takeda Pharmaceutical TAK Stock Holding History

Pinnacle Associates’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,775
Closed -$176K – 815
2021
Q3 		$176K Sell
10,775
-16,050
-60% -$269K ﹤0.01% 743
2021
Q2 		$451K Sell
26,825
-27,450
-51% -$467K 0.01% 562
2021
Q1 		$991K Buy
54,275
+3,975
+8% +$71.5K 0.02% 420
2020
Q4 		$915K Buy
50,300
+10,750
+27% +$189K 0.02% 406
2020
Q3 		$706K Sell
39,550
-61,065
-61% -$1.11M 0.02% 437
2020
Q2 		$1.8M Sell
100,615
-55,900
-36% -$1M 0.04% 283
2020
Q1 		$2.38M Sell
156,515
-4,625
-3% -$83.8K 0.07% 239
2019
Q4 		$3.18M Buy
161,140
+2,700
+2% +$51.7K 0.07% 254
2019
Q3 		$2.73M Buy
158,440
+10,383
+7% +$180K 0.06% 263
2019
Q2 		$2.62M Buy
148,057
+19,908
+16% +$362K 0.06% 272
2019
Q1 		$2.61M Buy
+128,149
New +$2.58M 0.06% 275

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pinnacle Associates's TAK Position: Q4 2021 in Review

Pinnacle Associates sold out of Takeda Pharmaceutical (TAK) in Q4 2021, closing a stake of 10,775 shares — an estimated $176K sold.

Pinnacle Associates first reported a position in TAK in Q1 2019 and held it in 11 quarters. The position peaked at $3.18M in Q4 2019. 298 funds tracked by Wall St. Rank hold TAK as of Q4 2021.

  • Pinnacle Associates reported no remaining Takeda Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • Pinnacle Associates sold 10,775 Takeda Pharmaceutical shares in Q4 2021, an estimated $176K.
  • Pinnacle Associates first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 11 quarters.
  • Pinnacle Associates's Takeda Pharmaceutical position peaked at $3.18M in Q4 2019.
  • 298 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2021.

Based on Pinnacle Associates's 13F filing for Q4 2021, filed 2 Feb 2022.